Get updates delivered to you daily. Free and customizable.
BioMed Central
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis
By Michael Trauner,
2023-03-15By Michael Trauner,
2023-03-15Read in NewsBreak
Comments / 0
Add a Comment
YOU MAY ALSO LIKE
Get updates delivered to you daily. Free and customizable.
Comments / 0